StockData

Neurogene vs Ovid Therapeutics

NGNE and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NGNE and OVID compare

Neurogene and Ovid Therapeutics are about the same size, with market caps of $462M and $434M.

Ovid Therapeutics scores higher on the StockData Score (10 against 7 for Neurogene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNGNEOVID
Size and price
Market cap$462M$434M
Share price$23.10$2.22
Change, 1 year1.4%70.1%
Change, 5 years−77.4%−31.9%
Beta (5Y)2.011.34
Employees13123
StockData Score
Total score710 (better)
Valuation score11
Growth score01 (better)
Performance score12 (better)
Health score56 (better)
Dividend score00
Valuation
P/S–274×
P/B2.1×2.1× (better)
FCF yield−19.0%–
Growth
Revenue growth (TTM)–−76.2%
Revenue growth, 5Y average–−10.5%
Profitability
Operating margin–−3687%
Net margin–−2179%
Return on equity−45.3%−26.0% (better)
Return on invested capital–−160%
Financial health
Debt / equity0.000.00
Interest coverage−60673.0×–
Current ratio10.6412.39 (better)
Altman Z-score7.179.41 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions86.5%75.3%
Held by insiders15.9%13.6%
Insider net buying, 12 months−$1.1M−$29.3K (better)
Short interest, % of float33.8%10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.